Monopar Advances Phase 1 Trial for MNPR-101-Lu in Cancer
![Monopar Advances Phase 1 Trial for MNPR-101-Lu in Cancer](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.
MNPR-101-Lu Overview
MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101, which is highly selective against the urokinase plasminogen activator receptor (uPAR). The MNPR-101-Lu Phase 1 clinical trial will enroll patients with advanced solid cancers and will be a therapeutic follow-on study to the currently ongoing MNPR-101-Zr imaging and dosimetry clinical trial.
Preclinical Study Insights
The results from preclinical studies of MNPR-101-Lu are promising. In a 90-day efficacy study in a human pancreatic cancer xenograft mouse model, MNPR-101-Lu demonstrated durable antitumor effects after a single injection, achieving complete elimination of tumors that lasted the duration of the study.
Therapeutic Effectiveness and Future Outlook
Imaging data on MNPR-101-Lu in a human pancreatic cancer xenograft mouse model provides additional insight into the strong therapeutic effect observed after a single injection of MNPR-101-Lu. The imaging data demonstrates the high specificity and durable uptake of MNPR-101-Lu in the tumor relative to normal tissue.
“We are excited about the HREC clearance and encouraged by the potential of MNPR-101-Lu to provide a meaningful clinical benefit to patients with uPAR-positive tumors. Several of the most aggressive, deadly cancers express uPAR, including triple negative breast cancer and pancreatic cancer,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “We are looking forward to launching the trial as quickly as we can.”
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101-Lu and MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development programs against solid cancers. For more information, visit: www.monopartx.com.
Frequently Asked Questions
What is the MNPR-101-Lu trial focused on?
The MNPR-101-Lu trial is focused on evaluating the effectiveness of a novel radiopharmaceutical in treating patients with advanced solid cancers.
What does MNPR-101-Lu combine?
MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with a proprietary humanized monoclonal antibody, MNPR-101.
What preclinical studies have been conducted?
A 90-day efficacy study in a human pancreatic cancer xenograft mouse model showed durable antitumor effects from a single injection of MNPR-101-Lu.
What is the potential benefit of MNPR-101-Lu?
MNPR-101-Lu is expected to provide a meaningful clinical benefit to patients with uPAR-positive tumors.
Who is Monopar Therapeutics?
Monopar Therapeutics is a clinical-stage company developing innovative treatments for cancer, including various radiopharmaceuticals aimed at different types of cancer.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/